| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e26de8d88c7b32804d869e560ae6ac52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 |
| filingDate |
2001-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eeaaad9594dad76344cc99bdedadf50b |
| publicationDate |
2001-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0174384-A1 |
| titleOfInvention |
Combined interferon alfa and liposomal-encapsulated all-trans retinoic acid, including preparation and use |
| abstract |
Alfa interferon (α-IFN or alpha-interferon) and liposomal all-trans retinoic acid is useful in cancer treatment with particular reference to renal cancer. Optionally, a regimen of α-interferon from about 3 to about 5 million units sc daily and liposomal all-trans retinoic acid at from a bout 15 mg/m2 to about 90mg/m2, or about 140mg/m2, or about 300mg/m2 or more. Dosage periodicity of about three times per week for both drugs in about 8 week cycles is useful. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019094626-A1 |
| priorityDate |
2000-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |